CAR-T cells for AML: Where do we stand?
49:06
Post #ASH24 Most Important CLL Studies
49:11
MRD in Acute Lymphoblastic Leukemia: Where do we Stand
47:34
How to Get Published: a Few Tips
1:40:26
IACH live summary from #ASH24
43:48
Post #ASH24 Most Important Cellular Therapy Studies
57:36
Public webinar - Preparing for IFRA’s revised policy on furocoumarins
32:59
Management of Waldenstrom disease: an update
53:00